Related references
Note: Only part of the references are listed.Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Jacalyn Rosenblatt et al.
BLOOD (2017)
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P. Moreau et al.
LEUKEMIA (2017)
Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
Frank (Xiaohu) Fan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Drugs that lack single-agent activity: are they worth pursuing in combination?
Bishal Gyawali et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dan T. Vogl et al.
CLINICAL CANCER RESEARCH (2017)
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
Niels W. C. J. van de Donk et al.
BLOOD (2016)
Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant
Sameh Gaballa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
How I treat acute myeloid leukemia presenting with preexisting comorbidities
Yishai Ofran et al.
BLOOD (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Rachid C. Baz et al.
BLOOD (2016)
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
S. Vincent Rajkumar et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Treatment of relapsed and refractory multiple myeloma
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
The True NTH Prostate Cancer Survivorship Care programme: Development and evaluation of a model for delivering follow-up care to men with prostate cancer.
Alison Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
Progress in Myeloma - A Monoclonal Breakthrough
S. Vincent Rajkumar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Treatment of relapsed and refractory multiple myeloma
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook et al.
LANCET HAEMATOLOGY (2016)
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Sergio Giralt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J. Shah et al.
BLOOD (2015)
Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling
Fabio Conforti et al.
CLINICAL CANCER RESEARCH (2015)
Hospitalization Rates Among Survivors of Young Adult Malignancies
Devon P. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation
C. O. Freytes et al.
BONE MARROW TRANSPLANTATION (2014)
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
Gordon Cook et al.
LANCET ONCOLOGY (2014)
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Y-T Tai et al.
LEUKEMIA (2014)
Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation
D. Zamarin et al.
BONE MARROW TRANSPLANTATION (2013)
Second autologous transplant as salvage therapy in multiple myeloma
Djordje Atanackovic et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution
Natalia Tovar et al.
HAEMATOLOGICA (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
Francesca Patriarca et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
Jan B. Egan et al.
BLOOD (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
C. S. Chim et al.
ANNALS OF HEMATOLOGY (2010)
Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience
Mariel Emilce Alejandre et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2010)
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation
Jennifer S. Carew et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
H. de Lavallade et al.
BONE MARROW TRANSPLANTATION (2008)
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
